BridgeBio Oncology Therapeutics, Inc. BBOT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.96M | 6.38M | 5.33M | 14.13M | 2.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.19M | 46.18M | 43.41M | 49.18M | 30.09M |
| Operating Income | -60.19M | -46.18M | -43.41M | -49.18M | -30.09M |
| Income Before Tax | -56.45M | -42.11M | -38.80M | -44.76M | -28.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.45M | -42.11M | -38.80M | -44.76M | -28.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.45M | -42.11M | -38.80M | -44.76M | -28.44M |
| EBIT | -60.19M | -46.18M | -43.41M | -49.18M | -30.09M |
| EBITDA | -60.11M | -46.11M | -43.32M | -49.11M | -30.02M |
| EPS Basic | -0.71 | -0.53 | -0.49 | -1.03 | -566.46 |
| Normalized Basic EPS | -0.44 | -0.33 | -0.30 | -0.64 | -354.04 |
| EPS Diluted | -0.71 | -0.53 | -0.49 | -1.03 | -566.46 |
| Normalized Diluted EPS | -0.44 | -0.33 | -0.30 | -0.64 | -354.04 |
| Average Basic Shares Outstanding | 80.05M | 80.03M | 79.99M | 43.49M | 50.20K |
| Average Diluted Shares Outstanding | 80.05M | 80.03M | 79.99M | 43.49M | 50.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |